Acetyl-cinobufagin suppresses triple-negative breast cancer progression by inhibiting the STAT3 pathway
BACKGROUND: The incidence of breast cancer (BC) worldwide has increased substantially in recent years. Epithelial-mesenchymal transition (EMT) refers to a crucial event impacting tumor heterogeneity. Although cinobufagin acts as an effective anticancer agent, the clinical use of cinobufagin is limited due to its strong toxicity. Acetyl-cinobufagin, a pre-drug of cinobufagin, was developed and prepared with greater efficacy and lower toxicity.
METHODS: A heterograft mouse model using triple negative breast cancer (TNBC) cell lines, was used to evaluate the potency of acetyl-cinobufagin. Signal transducer and stimulator of transcription 3 (STAT3)/EMT involvement was investigated by gene knockout experiments using siRNA and Western blot analysis.
RESULTS: Acetyl-cinobufagin inhibited proliferation, migration, and cell cycle S/G2 transition and promoted apoptosis in TNBC cells in vitro. In general, IL6 triggered the phosphorylation of the transcription factor STAT3 thereby activating the STAT3 pathway and inducing EMT. Mechanistically, acetyl-cinobufagin suppressed the phosphorylation of the transcription factor STAT3 and blocked the interleukin (IL6)-triggered translocation of STAT3 to the cell nucleus. In addition, acetyl-cinobufagin suppressed EMT in TNBC by inhibiting the STAT3 pathway. Experiments in an animal model of breast cancer clearly showed that acetyl-cinobufagin was able to reduce tumor growth.
CONCLUSIONS: The findings of this study support the potential clinical use of acetyl-cinobufagin as a STAT3 inhibitor in TNBC adjuvant therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Aging - 15(2023), 16 vom: 28. Aug., Seite 8258-8274 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Qi, Yufeng [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.09.2023 Date Revised 30.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.18632/aging.204967 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361492030 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361492030 | ||
| 003 | DE-627 | ||
| 005 | 20231226085242.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18632/aging.204967 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1204.xml |
| 035 | |a (DE-627)NLM361492030 | ||
| 035 | |a (NLM)37651362 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Qi, Yufeng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Acetyl-cinobufagin suppresses triple-negative breast cancer progression by inhibiting the STAT3 pathway |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.09.2023 | ||
| 500 | |a Date Revised 30.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: The incidence of breast cancer (BC) worldwide has increased substantially in recent years. Epithelial-mesenchymal transition (EMT) refers to a crucial event impacting tumor heterogeneity. Although cinobufagin acts as an effective anticancer agent, the clinical use of cinobufagin is limited due to its strong toxicity. Acetyl-cinobufagin, a pre-drug of cinobufagin, was developed and prepared with greater efficacy and lower toxicity | ||
| 520 | |a METHODS: A heterograft mouse model using triple negative breast cancer (TNBC) cell lines, was used to evaluate the potency of acetyl-cinobufagin. Signal transducer and stimulator of transcription 3 (STAT3)/EMT involvement was investigated by gene knockout experiments using siRNA and Western blot analysis | ||
| 520 | |a RESULTS: Acetyl-cinobufagin inhibited proliferation, migration, and cell cycle S/G2 transition and promoted apoptosis in TNBC cells in vitro. In general, IL6 triggered the phosphorylation of the transcription factor STAT3 thereby activating the STAT3 pathway and inducing EMT. Mechanistically, acetyl-cinobufagin suppressed the phosphorylation of the transcription factor STAT3 and blocked the interleukin (IL6)-triggered translocation of STAT3 to the cell nucleus. In addition, acetyl-cinobufagin suppressed EMT in TNBC by inhibiting the STAT3 pathway. Experiments in an animal model of breast cancer clearly showed that acetyl-cinobufagin was able to reduce tumor growth | ||
| 520 | |a CONCLUSIONS: The findings of this study support the potential clinical use of acetyl-cinobufagin as a STAT3 inhibitor in TNBC adjuvant therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a STAT3 | |
| 650 | 4 | |a STAT3 inhibitor | |
| 650 | 4 | |a acetyl-cinobufagin | |
| 650 | 4 | |a epithelial-mesenchymal transition | |
| 650 | 4 | |a triple negative breast cancer | |
| 650 | 7 | |a cinobufagin |2 NLM | |
| 650 | 7 | |a T9PSN4R8IR |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Bufanolides |2 NLM | |
| 650 | 7 | |a STAT3 protein, human |2 NLM | |
| 650 | 7 | |a STAT3 Transcription Factor |2 NLM | |
| 700 | 1 | |a Wu, Haodong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Tianru |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zitian |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Conghui |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Congzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Zhixuan |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Yiying |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Lehe |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Dezhi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xiaohua |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Haiyang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Chengguang |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Xuanxuan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Aging |d 2008 |g 15(2023), 16 vom: 28. Aug., Seite 8258-8274 |w (DE-627)NLM192249398 |x 1945-4589 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:16 |g day:28 |g month:08 |g pages:8258-8274 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18632/aging.204967 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 16 |b 28 |c 08 |h 8258-8274 | ||